ALDX
Aldeyra TheNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$92.68M
P/E Ratio
—
EPS
$-0.56
Beta
1.33
52W High
$6.17
52W Low
$1.07
50-Day MA
$4.20
200-Day MA
$4.81
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-35.01M |
| Operating Margin | 0.00% |
| Return on Equity | -58.70% |
| Return on Assets | -24.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.74 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 6.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.18M |
| Float | $48.56M |
| % Insiders | 3.20% |
| % Institutions | 65.70% |
Analyst Ratings
Consensus ($7.50 target)
1
Strong Buy3
Buy1
HoldData last updated: 4/7/2026